close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neumora Therapeutics, Inc. - Common Stock (NQ:NMRA)

0.3296 -0.0404 (-10.92%)
Delayed Quote Updated: 1:44 PM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neumora Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch. ↗
One of J&J's investments stands head-and-shoulders above the rest. 
Via The Motley Fool
News headline image
Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026
Company plans to submit an IND in the fourth quarter of 2026 and to initiate Phase 1 study by the end of 2026 
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraud
From Levi & Korsinsky, LLP
Via Business Wire
Which stocks are moving after the closing bell on Tuesday? ↗
Via Chartmill
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
Monday's session: top gainers and losers ↗
Via Chartmill
Gapping stocks in Monday's session ↗
Via Chartmill
News headline image
Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare Conference
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From Schall Law Firm
Via Business Wire
News headline image
Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
This Fund Put $3.4 Million Into Navan Despite a 60% Post-IPO Drop ↗
Navan delivers AI-powered travel and expense management software for enterprise clients seeking streamlined operations. 
Via The Motley Fool
Topics Artificial Intelligence Initial Public Offering Regulatory Compliance
News headline image
Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer’s Disease Agitation
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Top movers in Tuesday's pre-market session ↗
As the US market prepares to open on Tuesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Neumora Therapeutics to Participate in Upcoming Conferences in November
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Unusual volume stocks in Thursday's session ↗
Discover the stocks with unexpected trading volume in today's session on the US markets. 
Via Chartmill
News headline image
Unusual volume stocks in Wednesday's session ↗
In today's session, these stocks are experiencing unusual volume. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Neumora Therapeutics’ Experimental Drug Demonstrates Weight Loss in Preclinical Studies ↗
Neumora said that NMRA-215 demonstrated weight loss of up to 19% as a monotherapy and 26% in combination with Semaglutide. 
Via Stocktwits
News headline image
Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model
From Neumora Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.